Cell-free DNA in the surveillance of heart transplant rejection

Sharma, Dhruva; Subramaniam, Ganapathy; Sharma, Neha; Sharma, Pankaj

doi:10.1007/s12055-020-01130-9

Cited by 2 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analyzing dd-cfDNA has shown great potential as a biomarker for monitoring the allograft health, where an increase of the dd-cfDNA fraction in the recipient's bloodstream will indicate organ damage [2,[8][9][10][11][12]. As a noninvasive marker for organ health, dd-cfDNA testing has been applied for various organs [3,6], including the heart [13][14][15][16][17][18][19][20][21][22], kidney [5,[23][24][25][26][27][28][29], liver [11,29], lung [30][31][32], and pancreas and simultaneously pancreas-kidney transplantation [33].…”

Section: Introductionmentioning

confidence: 99%

Droplet digital PCR-based testing for donor-derived cell-free DNA in transplanted patients as noninvasive marker of allograft health: Methodological aspects

et al. 2023

View full text Add to dashboard Cite

In solid organ transplantation, donor-derived cell-free DNA (dd-cfDNA) is a promising universal noninvasive biomarker for allograft health, where high levels of dd-cfDNA indicate organ damage. Using Droplet Digital PCR (ddPCR), we aimed to develop an assay setup for monitoring organ health. We aimed to identify the least distinguishable percentage-point increase in the fraction of minute amounts of cfDNA in a large cfDNA background by using assays targeting single nucleotide polymorphisms (SNPs). We mimicked a clinical sample from a recipient in a number of spike-in experiments, where cfDNA from healthy volunteers were mixed. A total of 40 assays were tested and approved by qPCR and ddPCR. Limit of detection (LOD) was demonstrated to be approximately 3 copies per reaction, observed at a fraction of 0.002%, and which would equal 6 copies per mL plasma. Limit of quantification (LOQ) was 35 copies per reaction, estimated to 0.038%. The lowest detectable increase in percentage point of dd-cfDNA was approximately 0.04%. Our results demonstrated that ddPCR has great sensitivity, high precision, and exceptional ability to quantify low levels of cfDNA. The ability to distinguish small differences in mimicking dd-cfDNA was far beyond the desired capability. While these methodological data are promising, further prospective studies are needed to determine the clinical utility of the proposed method.

show abstract

Section: Introductionmentioning

confidence: 99%

Droplet digital PCR-based testing for donor-derived cell-free DNA in transplanted patients as noninvasive marker of allograft health: Methodological aspects

et al. 2023

View full text Add to dashboard Cite

show abstract

Curbing Proteastasis to Combat Antibody-Mediated Rejection Post Lung Transplant

Sharma

Subramaniam

2023

Indian Journal of Transplantation

View full text Add to dashboard Cite

Lung transplantation (LTx) has emerged as the treatment of choice for patients suffering from end-stage lung disease all over the past 35 years. Despite ameliorated early survival with a median survival of 6.5 years, its long-term outcomes are dissatisfactory. Although antibody-mediated rejection (AMR) remained “the Achilles heel of LTx,” yet we have not attained consensus on the optimal therapeutic approach. The aim of this review article is to address the upcoming role of proteasome inhibitor drugs in managing AMR post-LTx.

show abstract

Cell-free DNA in the surveillance of heart transplant rejection

Cited by 2 publications

References 55 publications

Droplet digital PCR-based testing for donor-derived cell-free DNA in transplanted patients as noninvasive marker of allograft health: Methodological aspects

Droplet digital PCR-based testing for donor-derived cell-free DNA in transplanted patients as noninvasive marker of allograft health: Methodological aspects

Curbing Proteastasis to Combat Antibody-Mediated Rejection Post Lung Transplant

Contact Info

Product

Resources

About